pafuramidine maleate Report issue

Small molecule Experimental
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Pafuramidine is an experimental drug for the treatment of pneumocystis pneumonia (PCP). In 2006, pafuramidine was given orphan drug status by the US Food and Drug Administration for PCP in patients with HIV/AIDS. Preliminary clinical trials indicated that pafuramide was effective against pneumocystis pneumonia and had the potential for fewer side effects than the standard treatment with trimethoprim/sulfamethoxazole (TMP-SMX).   Wikipedia

Chemistry

  • SMILES: CONC(=N)c1ccc(cc1)c2oc(cc2)c3ccc(cc3)C(=N)NOC
  • InChIKey: UKOQVLAXCBRRGH-UHFFFAOYSA-N
  • Mol. Mass: 364.41
  • ALogP: 3.57
  • ChEMBL Molecules:
    pafuramidine  
    pafuramidine maleate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

2,5-bis(4-amidinophenyl)furan-bis-o-methylamidoxime | db289 | db 289 | db-289 | db289 cpd | pafuramidine | pafuramidine maleate

Organizations (13)

Research & Development (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Healthy Volunteers (Phase 1)

HIV Infections (Phase 3)

Malaria (Phase 2)

Pneumonia, Pneumocystis (Phase 3)

Trypanosomiasis, African (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial Organizations: 13

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue